about
Usefulness of lipid apheresis in the treatment of familial hypercholesterolemiaMonogenic hypercholesterolemia: new insights in pathogenesis and treatmentGene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosisEfficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia.Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.Dementia Improvement after Plasma Exchange for Familial Hypercholesterolemia.LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection.State of the art of low-density lipoprotein apheresis in the year 2003.Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemiaLow-density lipoprotein apheresis: an evidence-based analysisThe lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Therapeutic apheresis--state of the art in the year 2005.Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management.The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.Successful treatment of homozygous familial hypercholesterolemia using cascade filtration plasmapheresis.Treatment of familial hypercholesterolemia: is there a need beyond statin therapy?Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.LDL apheresis and inflammation--implications for atherosclerosis.The use of therapeutic apheresis in cardiovascular disease.A current approach to statin intolerance.Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.Lipoprotein apheresis to treat elevated lipoprotein (a)Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment.Lipid apheresis techniques: current status in Germany.Recyclable heparin and chitosan conjugated magnetic nanocomposites for selective removal of low-density lipoprotein from plasma.Reduction of low-density lipoprotein cholesterol, plasma viscosity, and whole blood viscosity by the application of pulsed corona discharges and filtration.Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years.Direct adsorption of lipoproteins from whole blood by direct adsorption of lipoprotein apheresis: first experience in two hypercholesterolemic children.Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation.Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles.Synthesis and in vitro sorption properties of PAA-grafted cellulose beads for selective binding of LDL.Modeling and simulation of nanoparticle separation through a solid-state nanopore.Familial hypercholesterolemia.A Discussion on the Relationship between Skin Lipid Metabolism and Whole-Body Glucose and Lipid Metabolism: Systematic Review
P2860
Q21284511-DDE638DD-C5A6-46AF-B6E4-9F37CBE59CA0Q24672834-6A4B6C36-260B-4D70-811A-56E5AAF0B341Q28748804-BD0E57A0-F184-4620-99CA-300BF317B6A9Q33567315-F297CE32-90B3-4515-B676-BDBA1FF7C493Q33580086-86AE87FC-0D72-4F13-963B-97F88447CE42Q34122035-7D78A204-68D6-49F6-8EE9-E7D3D9808E4CQ34284716-F26F8A9F-9999-4DC8-87C8-23C43F846122Q34541236-C40FA9F2-9D71-4E16-A0DF-7DBC128D7DB3Q35768586-355ED05F-C6B1-4D56-B411-45372D8E79EDQ35837148-11E1027A-D1B8-45C6-AFC7-15B6ED238752Q35839693-E394135B-4BAC-4B45-AA7B-BB69A35EE40DQ36040181-59CB8F0F-202A-4FBC-8F1B-E0E1E772C9CBQ36069577-F9164985-63C8-47E3-86F3-1F2DBEA302E4Q36341821-C0DEC35A-3E59-42C8-AC58-42191F640C8EQ36739895-C4613DA1-5C6B-422C-82CB-373F5B7FC36FQ36925157-4F88B6C8-98ED-4EEB-9B83-9A466C4A6C9CQ37193865-CC75D38A-6F34-49D5-B97B-A4B749D93FFCQ37963825-B86325E9-404B-4233-B46C-75BAE84ECFABQ37965588-F10EED68-FB04-4968-94D4-94C893930D4EQ38016475-F8985773-E39C-40CC-8CE9-28A5EF342443Q38203567-52348A1A-49FF-4F57-A820-1D1CE91FD620Q38204184-D65E1753-F7C1-4E03-A160-3030B293BBC1Q38325807-0960A3DF-0D05-4117-9C64-24B1A1C2CFA0Q38738379-1E6CDE13-9A92-4278-93FD-F12CB6207783Q38776037-B4B728CF-0C22-454D-8598-5404E4E83CABQ40707724-C52C2ADD-DCBE-45FF-80B3-8D8A4F456A98Q42199887-34B667F7-7789-4E51-8DD3-D67163E79197Q43311166-5E5E5433-3783-4A3F-AE90-89C21522558CQ43817566-CD09EC27-E99E-45A6-AFA8-76E58BED1833Q45032463-F534765B-DB7B-47A8-96D8-8B54D8C03DE2Q46850991-7B56EC9D-7FBB-4EA5-A229-C44B6008DBAAQ46903624-E67834BC-72B4-4BF6-A5A2-1EF4AFFF96BAQ47246011-B4EF6C8D-C8C6-426E-AD5A-D7339EE1C72FQ51150124-A5BF646B-D4C9-43F5-88BE-93D9459837B9Q51456628-2101CD09-AFA0-42CF-8C9A-A32478C4C451Q55284678-EA826E59-C254-4EA3-9CCC-7C0C352F65DFQ59125135-4600E2FC-6584-479A-BABB-00E7D3029E71
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
LDL apheresis.
@ast
LDL apheresis.
@en
LDL apheresis.
@nl
type
label
LDL apheresis.
@ast
LDL apheresis.
@en
LDL apheresis.
@nl
prefLabel
LDL apheresis.
@ast
LDL apheresis.
@en
LDL apheresis.
@nl
P1433
P1476
LDL apheresis.
@en
P2093
Gilbert R Thompson
P356
10.1016/S0021-9150(02)00251-4
P577
2003-03-01T00:00:00Z